GlobalData on MSN21h
SK bioscience and Sanofi’s GBP410 vaccine enters global Phase III trials
SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...
pulmonologyadvisor11d
Pneumococcal Vaccine V116 Reduces Disease Burden, Cost-Effective in Older Adults
V116 (PCV21) was more cost-effective than PCV20 alone and PCV15 plus PPSV23 for the prevention of adult pneumococcal disease.
McKnight's Long-Term Care News11d
CDC widens pneumococcal vaccine recommendation to all over 50
The Centers for Disease Control and Prevention (CDC) now recommends that American adults over the age of 50 receive the ...
Yahoo Finance29d
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...
FierceBiotech29d
Sanofi pays SK bioscience €50M as children's pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3. The move follows a phase 2 win last ...
Benzinga.com29d
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Separately, the analyst flagged Pfizer management’s mention of the fourth generation 25-valent pneumococcal vaccine (PCV), which management affirms continues to progress in Phase 2. Shibutani ...
PharmiWeb19d
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate ...